Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study - PubMed (original) (raw)
Comparative Study
. 2004 May;161(5):826-35.
doi: 10.1176/appi.ajp.161.5.826.
Affiliations
- PMID: 15121647
- DOI: 10.1176/appi.ajp.161.5.826
Comparative Study
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study
Jeffrey H Meyer et al. Am J Psychiatry. 2004 May.
Abstract
Objective: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [(11)C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic doses. The relationship between dose and occupancy was also investigated.
Method: Striatal 5-HTT binding potential was measured in 77 subjects before and after 4 weeks of medication administration. Binding potential is proportional to the density of receptors not blocked by medication. Subjects received citalopram, fluoxetine, sertraline, paroxetine, or extended-release venlafaxine. Healthy subjects received subtherapeutic doses; subjects with mood and anxiety disorders received therapeutic doses. Percent reduction in 5-HTT binding potential for each medication and dose was calculated. To obtain test-retest data, binding potential was measured before and after 4 weeks in six additional healthy subjects.
Results: Substantial occupancy occurred at subtherapeutic doses for all SSRIs. Compared to test-retest data, each drug at the minimum therapeutic dose had a significant effect on striatal 5-HTT binding potential. Mean occupancy at this dose was 76%-85%. At higher plasma SSRI concentrations, 5-HTT occupancy tended to increase above 80%. For each drug, as the dose (or plasma level) increased, occupancy increased nonlinearly, with a plateau for higher doses.
Conclusions: At tolerable doses, SSRIs have increasing occupancy with increasing plasma concentration or dose. Occupancy of 80% across five SSRIs occurs at minimum therapeutic doses. This suggests that 80% 5-HTT blockade is important for therapeutic effect. Occupancy should be measured during development of antidepressant compounds targeting the 5-HTT.
Similar articles
- Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.
Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. Meyer JH, et al. Am J Psychiatry. 2001 Nov;158(11):1843-9. doi: 10.1176/appi.ajp.158.11.1843. Am J Psychiatry. 2001. PMID: 11691690 Clinical Trial. - Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.
Voineskos AN, Wilson AA, Boovariwala A, Sagrati S, Houle S, Rusjan P, Sokolov S, Spencer EP, Ginovart N, Meyer JH. Voineskos AN, et al. Psychopharmacology (Berl). 2007 Sep;193(4):539-45. doi: 10.1007/s00213-007-0806-z. Epub 2007 May 12. Psychopharmacology (Berl). 2007. PMID: 17497139 Clinical Trial. - [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Ginovart N, et al. Synapse. 2003 Feb;47(2):123-33. doi: 10.1002/syn.10155. Synapse. 2003. PMID: 12454950 - A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Sanchez C, Reines EH, Montgomery SA. Sanchez C, et al. Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Int Clin Psychopharmacol. 2014. PMID: 24424469 Free PMC article. Review. - Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.
Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brücke T. Kasper S, et al. World J Biol Psychiatry. 2002 Jul;3(3):133-46. doi: 10.3109/15622970209150614. World J Biol Psychiatry. 2002. PMID: 12478878 Review.
Cited by
- Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.
Zhang MM, Tan X, Zheng YB, Zeng N, Li Z, Horowitz MA, Feng XZ, Wang K, Li ZY, Zhu WL, Zhou X, Xie P, Zhang X, Wang Y, Shi J, Bao YP, Lu L, Li SX. Zhang MM, et al. Mol Psychiatry. 2024 Oct 11. doi: 10.1038/s41380-024-02782-4. Online ahead of print. Mol Psychiatry. 2024. PMID: 39394455 - Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study.
Brouwer JMJL, Wardenaar KJ, Nolte IM, Liemburg EJ, Bet PM, Snieder H, Mulder H, Cath DC, Penninx BWJH. Brouwer JMJL, et al. BMC Psychiatry. 2024 May 27;24(1):394. doi: 10.1186/s12888-024-05764-6. BMC Psychiatry. 2024. PMID: 38797832 Free PMC article. - Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
Liao Y, Sun Y, Guo J, Kang Z, Sun Y, Zhang Y, He J, Huang C, Sun X, Zhang JM, Wang J, Wang HN, Chen ZY, Wang K, Pan J, Ni AH, Weng S, Wang A, Cao C, Sun L, Zhang Y, Kuang L, Zhang Y, Liu Z, Yue W; Precision Medicine to Enhance Depression and Anxiety Outcome Consortium. Liao Y, et al. EBioMedicine. 2024 Jun;104:105165. doi: 10.1016/j.ebiom.2024.105165. Epub 2024 May 21. EBioMedicine. 2024. PMID: 38776596 Free PMC article. - The utility of PET imaging in depression.
Singh SB, Tiwari A, Katta MR, Kafle R, Ayubcha C, Patel KH, Bhattarai Y, Werner TJ, Alavi A, Revheim ME. Singh SB, et al. Front Psychiatry. 2024 Apr 22;15:1322118. doi: 10.3389/fpsyt.2024.1322118. eCollection 2024. Front Psychiatry. 2024. PMID: 38711875 Free PMC article. Review. - Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.
Sakai K, Bradley ER, Zamaria JA, Agin-Liebes G, Kelley DP, Fish A, Martini V, Ferris MC, Morton E, Michalak EE, O'Donovan A, Woolley JD. Sakai K, et al. Psychopharmacology (Berl). 2024 Aug;241(8):1617-1630. doi: 10.1007/s00213-024-06585-x. Epub 2024 Apr 30. Psychopharmacology (Berl). 2024. PMID: 38687360
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources